...
bcab-img

Bioatla Inc, Common Stock

BCAB

NMQ

$1.45

+$0.02

(1.4%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$73.97M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
305.06K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.02
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.14 L
$4.02 H
$1.45

About Bioatla Inc, Common Stock

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameBCABSectorS&P500
1-Week Return-11.59%-2.27%-0.57%
1-Month Return-27.14%-3.96%1.21%
3-Month Return-19.89%-9.7%7.57%
6-Month Return-7.64%-3.37%11.45%
1-Year Return-31.6%3.71%28.48%
3-Year Return-93.35%3.8%29.52%
5-Year Return-95.33%39.78%90.66%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue5.20M429.00K250.00K--[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":8.25,"profit":true},{"date":"2021-12-31","value":4.81,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue25.92K19.93K1.33M1.20M103.73M[{"date":"2019-12-31","value":0.02,"profit":true},{"date":"2020-12-31","value":0.02,"profit":true},{"date":"2021-12-31","value":1.28,"profit":true},{"date":"2022-12-31","value":1.16,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit5.17M409.07K(1.08M)(1.20M)(103.73M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":7.91,"profit":true},{"date":"2021-12-31","value":-20.87,"profit":false},{"date":"2022-12-31","value":-23.17,"profit":false},{"date":"2023-12-31","value":-2004.82,"profit":false}]
Gross Margin99.50%95.35%(432.00%)--[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":95.83,"profit":true},{"date":"2021-12-31","value":-434.16,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses33.47M30.53M96.69M108.14M129.69M[{"date":"2019-12-31","value":25.81,"profit":true},{"date":"2020-12-31","value":23.54,"profit":true},{"date":"2021-12-31","value":74.56,"profit":true},{"date":"2022-12-31","value":83.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(28.27M)(30.10M)(96.44M)(108.14M)(129.69M)[{"date":"2019-12-31","value":-2826800000,"profit":false},{"date":"2020-12-31","value":-3009900000,"profit":false},{"date":"2021-12-31","value":-9644000000,"profit":false},{"date":"2022-12-31","value":-10814000000,"profit":false},{"date":"2023-12-31","value":-12968700000,"profit":false}]
Total Non-Operating Income/Expense(3.09M)(7.04M)1.39M3.31M11.95M[{"date":"2019-12-31","value":-25.86,"profit":false},{"date":"2020-12-31","value":-58.96,"profit":false},{"date":"2021-12-31","value":11.59,"profit":true},{"date":"2022-12-31","value":27.67,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(29.86M)(35.85M)(95.40M)(106.48M)(123.46M)[{"date":"2019-12-31","value":-2985500000,"profit":false},{"date":"2020-12-31","value":-3585300000,"profit":false},{"date":"2021-12-31","value":-9540200000,"profit":false},{"date":"2022-12-31","value":-10648200000,"profit":false},{"date":"2023-12-31","value":-12346200000,"profit":false}]
Income Taxes1.55M1.39M4.00K(1.20M)-[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":89.72,"profit":true},{"date":"2021-12-31","value":0.26,"profit":true},{"date":"2022-12-31","value":-77.5,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes(31.40M)(37.24M)(95.41M)(105.28M)-[{"date":"2019-12-31","value":-3140200000,"profit":false},{"date":"2020-12-31","value":-3724100000,"profit":false},{"date":"2021-12-31","value":-9540600000,"profit":false},{"date":"2022-12-31","value":-10528300000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(29.86M)(35.85M)(95.40M)(106.48M)(124.08M)[{"date":"2019-12-31","value":-2985500000,"profit":false},{"date":"2020-12-31","value":-3585300000,"profit":false},{"date":"2021-12-31","value":-9540200000,"profit":false},{"date":"2022-12-31","value":-10648200000,"profit":false},{"date":"2023-12-31","value":-12408000000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(31.40M)(37.24M)(95.41M)(105.28M)(123.46M)[{"date":"2019-12-31","value":-3140200000,"profit":false},{"date":"2020-12-31","value":-3724100000,"profit":false},{"date":"2021-12-31","value":-9540600000,"profit":false},{"date":"2022-12-31","value":-10528300000,"profit":false},{"date":"2023-12-31","value":-12346200000,"profit":false}]
EPS (Diluted)-(2.33)(2.76)(2.74)(2.59)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-233,"profit":false},{"date":"2021-12-31","value":-276,"profit":false},{"date":"2022-12-31","value":-274,"profit":false},{"date":"2023-12-31","value":-259.06,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

BCAB
Cash Ratio 2.90
Current Ratio 3.11

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

BCAB
ROA (LTM) -50.47%
ROE (LTM) -139.06%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

BCAB
Debt Ratio Lower is generally better. Negative is bad. 0.63
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.37

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

BCAB
Trailing PE NM
Forward PE NM
P/S (TTM) 6.37
P/B 3.05
Price/FCF NM
EV/R 1.24
EV/Ebitda 0.31

FAQs

What is Bioatla Inc share price today?

Bioatla Inc (BCAB) share price today is $1.45

Can Indians buy Bioatla Inc shares?

Yes, Indians can buy shares of Bioatla Inc (BCAB) on Vested. To buy Bioatla Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BCAB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Bioatla Inc be purchased?

Yes, you can purchase fractional shares of Bioatla Inc (BCAB) via the Vested app. You can start investing in Bioatla Inc (BCAB) with a minimum investment of $1.

How to invest in Bioatla Inc shares from India?

You can invest in shares of Bioatla Inc (BCAB) via Vested in three simple steps:

  • Click on Sign Up or Invest in BCAB stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Bioatla Inc shares
What is Bioatla Inc 52-week high and low stock price?

The 52-week high price of Bioatla Inc (BCAB) is $4.02. The 52-week low price of Bioatla Inc (BCAB) is $1.14.

What is Bioatla Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Bioatla Inc (BCAB) is

What is Bioatla Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Bioatla Inc (BCAB) is 3.05

What is Bioatla Inc dividend yield?

The dividend yield of Bioatla Inc (BCAB) is 0.00%

What is the Market Cap of Bioatla Inc?

The market capitalization of Bioatla Inc (BCAB) is $73.97M

What is Bioatla Inc’s stock symbol?

The stock symbol (or ticker) of Bioatla Inc is BCAB

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top